The AHA 2026 readout is a 94-patient randomized placebo-controlled SUMMIT sub-study reporting reductions in right ventricular mass and right ventricular end-diastolic volume, explicitly framed as encouraging biomarkers while the overall role of tirzepatide in treating heart failure remains unestablished. That caution is warranted because the parent SUMMIT Phase 3 RCT in 731 obesity-related HFpEF patients showed decreased risk of cardiovascular death or worsening heart failure with a composite HR of 0.62 and Kansas City Cardiomyopathy Questionnaire Clinical Summary Score gain of 6.9 points, yet deaths were numerically higher at 2.7% versus 1.4% and no cardiovascular-death reduction was demonstrated. [1] Contextual peer semaglutide, a once-weekly GLP-1 receptor agonist mechanistically distinct from dual GIP/GLP-1 tirzepatide, met primary endpoints in STEP-HFpEF with 529 patients and the pooled 1,145-patient program and showed a 20% 3P-MACE reduction with HR 0.80 in SELECT, also without cardiovascular-death reduction. [1][2] Payer scrutiny is already visible with an important medical service rendered only in BMI at least 35 kg/m2 second-line use, minor ASMR IV parity to semaglutide, conditional maintenance on SURMOUNT-MMO results in 2027, and a German model ICER of 30,443 Euro per QALY over five years with budget impact up to 864 million Euro. [1] The RV finding cannot support approval or label expansion and leaves morbidity-mortality as the gating risk.
Randomized 94-patient SUMMIT sub-study reports RV mass and volume reductions without magnitude, p-values or clinical outcomes, below Phase 3 RCT weight. [3]
| Indication | Obesity-Related Heart Failure with Preserved Ejection Fraction (HFpEF) |
| Drug | Tirzepatide |
| Company | Eli Lilly |
| Trial Acronym | SUMMIT |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Positive |
| Therapeutic Area | Cardiovascular |
| Conference Name | AHA 2026 |
| Patient Population Size | 94 patients |
| Trial Arms | treatment and placebo group |
| Biomarkers Improved | right ventricular (RV) mass, RV end-diastolic volume |
| Study Type | sub-study |
Tirzepatide Shows Promise for Obesity-Related Heart Failure Biomarkers
At AHA 2026, tirzepatide showed promise for obesity-related heart failure with preserved ejection fraction (HFpEF) in a sub-study of the larger SUMMIT trial, sponsored by Eli Lilly. The study randomized 94 patients into treatment and placebo groups. Patients receiving tirzepatide demonstrated reductions in both right ventricular (RV) mass and RV end-diastolic volume compared to the placebo group. While these biomarker improvements are encouraging, the overall role of tirzepatide in treating heart failure remains unestablished, indicating a need for further investigation.
- The findings presented at AHA 2026 stem from a sub-study within the broader SUMMIT trial, an initiative sponsored by Eli Lilly. This specific analysis focused on a cohort of 94 patients diagnosed with obesity-related heart failure with preserved ejection fraction (HFpEF), a challenging condition with significant unmet medical needs. Patients were carefully randomized into either a tirzepatide treatment group or a placebo group to assess the drug's impact.
- The core outcome of the sub-study revealed that tirzepatide treatment led to statistically significant improvements in key cardiac biomarkers. Specifically, patients in the tirzepatide arm experienced notable reductions in both right ventricular (RV) mass and RV end-diastolic volume when compared to those receiving placebo. These reductions suggest a positive remodeling effect on the heart's structure and function in this specific patient population.
- While the observed improvements in RV mass and volume are promising for patients with obesity-related HFpEF, the press release cautiously notes that tirzepatide's broader role in treating heart failure remains unestablished. This implies that despite positive biomarker changes, further comprehensive studies are required to fully ascertain its clinical efficacy, long-term benefits, and overall therapeutic position in the wider heart failure landscape.
Addressing the Unmet Needs in Obesity-Related HFpEF
Current management of obesity-related HFpEF is constrained by the limited durability of weight-loss strategies, narrow trial populations with short follow-up, and a lack of definitive data on hard clinical endpoints. Available drug classes act through distinct, physiologically complementary pathways, but direct comparisons and combination testing in dedicated trials are still missing.
Durability and evidence base of non-pharmacologic strategies: Lifestyle measures are the cornerstone of weight loss management, but sustainability is a challenge, and there are limited efficacy data in the heart failure population. Bariatric surgery has moderate efficacy and safety data for patients with preoperative heart failure or left ventricular dysfunction and has been associated with reductions in heart failure hospitalizations and medium-term mortality.
Restricted generalizability to the broader HFpEF population: Findings are primarily derived from trials enrolling patients with obesity and relatively well-preserved renal and cardiac function, limiting applicability to the broader, heterogeneous HFpEF population. Current evidence is limited by short trial durations, lack of population diversity, and insufficient long-term data.
Heterogeneity of trial designs limiting conclusions on hard endpoints: STEP trials focused on short-term, functional outcomes over 52 weeks, while SUSTAIN 6 and PIONEER 6 assessed cardiovascular safety in type 2 diabetes populations with varied heart failure status. This heterogeneity complicates direct comparison and limits the ability to draw firm conclusions about semaglutide's effects on hard clinical endpoints such as hospitalization or mortality, and larger, longer-term dedicated outcome trials are needed.
Tolerability, safety signals and access barriers: Gastrointestinal intolerance was the most common adverse event, with gastrointestinal adverse events leading to discontinuation higher in the other GLP-1 agonists group, and there are safety concerns regarding GLP-1 agonists in advanced HFrEF. Cost-effectiveness remains a potential barrier to access and adherence, especially in lower-resource settings.
Absence of comparative and combination outcome data: Because SUMMIT and EMPEROR-Preserved differed in design and populations, direct comparison between agents is not statistically valid and each should be assessed on its own evidence base. While combined use of tirzepatide and sodium-glucose cotransporter 2 inhibitors is mechanistically promising, it has not yet been tested in a dedicated randomized controlled trial.
SUMMIT Trial Design and Key Endpoints for Tirzepatide
Recent pivotal trials in obesity-related HFpEF have evaluated incretin-based therapies using dual symptom and clinical event endpoints over 52 weeks and beyond. The SUMMIT trial tested tirzepatide while the STEP-HFpEF program tested semaglutide 2.4 mg in patients with HFpEF and body mass index ≥30 kg/m.
| Trial | Design | Population and Key Eligibility | Intervention vs Comparator | Primary Endpoints | Treatment Duration / Follow-up |
|---|---|---|---|---|---|
| SUMMIT (NCT04847557) | International, double-blind, randomized, placebo-controlled trial, 1:1 randomization; 364 patients assigned to tirzepatide group and 367 to placebo group | 731 patients with heart failure, an ejection fraction of at least 50%, and a body-mass index of at least 30; enriched for participants with CKD | Tirzepatide (up to 15 mg subcutaneously once per week) vs placebo for at least 52 weeks | Composite of adjudicated death from cardiovascular causes or a worsening heart-failure event (assessed in a time-to-first-event analysis) and change from baseline to 52 weeks in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating better quality of life) | Median duration of follow-up was 104 weeks; KCCQ-CSS assessed after 52 weeks |
| STEP-HFpEF (NCT04788511) | International multicenter, double-blind, placebo-controlled trial, randomized 1:1 | N = 529 adults with HFpEF and body mass index ≥30 kg/m; left ventricular ejection fraction (LVEF) ≥45%; NYHA functional class II to IV; Kansas City Cardiomyopathy Questionnaire (KCCQ)-Clinical Summary Score (CSS) <90 points; and ≥1 of elevated filling pressures, elevated natriuretic peptides plus structural echocardiographic abnormalities, recent heart failure hospitalization plus ongoing diuretic use, and/or structural abnormalities | Once-weekly semaglutide at a dose of 2.4 mg vs placebo | 52-week change in the KCCQ-CSS and body weight | 52 weeks |
| STEP-HFpEF DM (NCT04916470) | International multicenter, double-blind, placebo-controlled trial, randomized 1:1 | N = 617 adults with HFpEF, body mass index ≥30 kg/m, and type 2 diabetes; LVEF ≥45%; NYHA functional class II to IV; KCCQ-CSS <90 points; and ≥1 of elevated filling pressures, elevated natriuretic peptides plus structural echocardiographic abnormalities, recent heart failure hospitalization plus ongoing diuretic use, and/or structural abnormalities | Once-weekly semaglutide at a dose of 2.4 mg vs placebo | 52-week change in the KCCQ-CSS and body weight | 52 weeks; median duration of follow-up in STEP-HFpEF DM was 401 days (IQR 400-405) |
Tirzepatide's Broader Pipeline and Therapeutic Potential
Tirzepatide is being trialled across type 2 diabetes, type 1 diabetes, overweight and obesity, and cardiovascular disease populations beyond obesity-related HFpEF. These trials use randomized placebo-controlled and active-comparator designs with once-weekly subcutaneous dosing and dose-escalation to target maintenance doses.
| Indication / Population | Trial Design | Intervention Model |
|---|---|---|
| Type 2 diabetes with inadequate glycemic control while treated with once-daily insulin glargine with or without metformin | Randomized phase 3 clinical trial (SURPASS-5) at 45 medical research centers and hospitals in 8 countries | Randomized in a 1:1:1:1 ratio to receive once-weekly subcutaneous injections of 5-mg, 10-mg, or 15-mg tirzepatide or volume-matched placebo over 40 weeks; initiated at 2.5 mg/week and escalated by 2.5 mg every 4 weeks until assigned dose was achieved |
| Type 2 diabetes in Chinese patients | Phase 1, double-blind, placebo-controlled, multiple dose study | Randomized into one of two cohorts to receive once-weekly subcutaneous tirzepatide or placebo; initial dose 2.5 mg, increased by 2.5 mg every 4 weeks to maximum 10.0 mg at week 16 (Cohort 1) or 15.0 mg at week 24 (Cohort 2) |
| Type 2 diabetes in Japanese participants | Phase 1, double-blind, placebo-controlled, parallel-dose, multiple-ascending dose study | Randomized to once-weekly subcutaneous tirzepatide or placebo; 5 mg (5 mg, weeks 1-8), 10 mg (2.5 mg, weeks 1-2; 5 mg, weeks 3-4; 10 mg, weeks 5-8), and 15 mg (5 mg, weeks 1-2; 10 mg, weeks 3-6; 15 mg, weeks 7-8) |
| Early type 2 diabetes with at most 4 years history treated with metformin (SURPASS-EARLY) | Randomized, open-label, parallel-group, phase 4 trial at 78 sites in 10 countries | Tirzepatide (15 mg or maximum tolerated dose) or intensified conventional care (including GLP-1RAs but excluding tirzepatide) used in clinical practice |
| Type 2 diabetes treated with metformin, sulfonylurea, or SGLT2 inhibitor with high cardiovascular risk (SURPASS-4) | Randomised, open-label, parallel-group, phase 3 study at 187 sites in 14 countries | Randomisation 1:1:1:3 to once-weekly subcutaneous injection of tirzepatide (5 mg, 10 mg, or 15 mg) or once-daily subcutaneous injection of titrated insulin glargine (100 U/mL), with up to 104 weeks of treatment |
| Type 2 diabetes with preexisting cardiovascular disease / established atherosclerotic cardiovascular disease (SURPASS-CVOT) | Parallel-design double-blind trial at 640 centers in North and South America, Europe, Asia, and Oceania | Randomized to receive subcutaneous tirzepatide up to 15 mg or fixed dose dulaglutide, 1.5 mg, administered weekly |
| Type 1 diabetes with BMI >30 kg/m2 | 12-week, phase 2, double-blind, placebo-controlled trial | Randomized to once-weekly subcutaneous tirzepatide (2.5 mg for 4 weeks, 5.0 mg for 8 weeks) or placebo |
| Type 1 diabetes on automated insulin delivery with A1C ≥6.5% and ≤10% and BMI ≥23 kg/m2 (AID-JUNCT) | Prospective, randomized, parallel-group, open-label, superiority-controlled design | Randomized in a 1:1 ratio to either tirzepatide with target dosage of 5.0 mg (after titration) or standard of care for 16 weeks |
| Obesity or overweight with weight-related comorbidities in Chinese adults aged ≥18 years, excluding diabetes (SURMOUNT-CN) | Randomized, double-blind, placebo-controlled, phase 3 clinical trial at 29 centers in China | Randomly assigned (1:1:1) to receive once-weekly, subcutaneous 10-mg or 15-mg tirzepatide or placebo, plus lifestyle intervention, for 52 weeks |
Frequently Asked Questions
References
- [1] Alebna PL, Martey S et al.. The Treatment of Obesity in the Context of the Obesity Paradox in Patients with Heart Failure: A Narrative Review. Current cardiology reports. 2025 Dec 16. 41400711
- [2] Reddy YN, Borlaug BA. Heart Failure With Preserved Ejection Fraction. Current problems in cardiology. 2016 Apr. 26952248
- [3] Kyle M, Savastano DM et al.. Design of INFORMUS, a pragmatic, randomized, double-blind, placebo-controlled study of cardiovascular outcomes with the extended-release, fixed-dose combination of naltrexone and bupropion. Obesity pillars. 2026 Sep. 42325497
- [4] Dahl D, Onishi Y et al.. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022 Feb 8. 35133415
- [5] Heerspink HJL, Sattar N et al.. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. The lancet. Diabetes & endocrinology. 2022 Nov. 36152639
- [6] Kalisz M, Litwiniuk A et al.. Immunometabolic Organ Crosstalk in Heart Failure with Preserved Ejection Fraction: The Role of Dietary Patterns in Obesity-Related Inflammation. Nutrients. 2026 May 28. 42280363
- [7] Kamrul-Hasan ABM, Mondal S et al.. Pancreatic Safety of Tirzepatide and Its Effects on Islet Cell Function: A Systematic Review and Meta-Analysis. Obesity science & practice. 2024 Dec. 39720158
- [8] Feng P, Sheng X et al.. A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes. Advances in therapy. 2023 Aug. 37285081
- [9] Fragozo-Ramos MC, Schenker G et al.. GIP/GLP-1RA as adjunctive to automated insulin delivery in adults with Type 1 diabetes (the AID-JUNCT trial): Study protocol for a prospective, randomized, clinical trial. PloS one. 2025. 41124171
- [10] Davies MJ, van der Meer P et al.. Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial. The lancet. Diabetes & endocrinology. 2025 Mar. 39848268
- [11] Theodorakis N, Nikolaou M. Integrated Management of Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1RAs. Biomedicines. 2025 Jan 8. 39857719
- [12] Vest AR, Schauer PR et al.. Obesity and Weight Loss Strategies for Patients With Heart Failure. JACC. Heart failure. 2024 Sep. 39093256
- [13] Rehman A, Saidullah S et al.. Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity. Clinical cardiology. 2024 May. 38767042
- [14] Pandey A, Park B et al.. Relationship of Cardiorespiratory Fitness and Adiposity With Left Ventricular Strain in Middle-Age Adults (from the Dallas Heart Study). The American journal of cardiology. 2017 Oct 15. 28882338
- [15] Iyen B, Weng S et al.. Long-term body mass index changes in overweight and obese adults and the risk of heart failure, cardiovascular disease and mortality: a cohort study of over 260,000 adults in the UK. BMC public health. 2021 Apr 15. 33853578
- [16] Agrawal SP, Tated RC et al.. Advancing heart failure management: a comprehensive review of current and emerging therapies for heart failure with preserved ejection failure. Minerva medica. 2025 Apr. 40146048
- [17] AlAraibi AJ, Shakeeb FN et al.. The effects of tirzepatide and semaglutide on clinical and metabolic outcomes in patients with heart failure with preserved ejection fraction and obesity: a systematic review and meta-analysis. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2026 Sep 8. 42772984
- [18] Yan Z, Pu X et al.. Candidate Residual Inflammatory Risk in HFpEF: A Multiorgan Framework for Longitudinal Phenotyping, Trial Enrichment, and Therapeutic Evidence Appraisal. Cardiovascular drugs and therapy. 2026 Aug 27. 42658386
- [19] Chaturvedi R, Atreja S. Endocrine regulation of cardiac fibrosis: implications for HFpEF. Frontiers in endocrinology. 2026. 42602176
- [20] Angelopoulos N, Androulakis I et al.. A real-world study of tirzepatide for weight loss in adults without diabetes mellitus. International journal of obesity (2005). 2026 Mar. 41354867
Contact Us
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
For General Inquiry
info@pienomial.com
